Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.06.2012 | short review

The role of biomarkers in the choice of therapy in breast cancer

verfasst von: Brigitte Mlineritsch, MD, Sigrun Ressler, MD, Prof. Richard Greil, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

The discovery of prognostic and predictive biomarkers, enabling the application of more individualized therapies to different molecular breast cancer (BC) subtypes, has already led to changes in BC treatment during the past decades. In this review, the importance of established as well as of emerging biomarkers, currently undergoing testing for technical validity and clinical utility, is discussed.
Vorheriger Artikel Natural killer cell based immunotherapy for eradication of minimal residual disease in patients with malignant disorders
Nächster Artikel Evolving strategies to overcome endocrine resistance in breast cancer
Literatur
1.
Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.CrossRefPubMed
2.
Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res. 2007;9:R28.CrossRefPubMed
3.
Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670–4.CrossRefPubMed
4.
Cuppone F, Bria E, Carlini P, et al. Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. Cancer. 2008;113(2):238–46.CrossRefPubMed
5.
Bedard PL, Di Leo A, Piccart-Gebhart MJ. Taxanes: optimizing adjuvant chemotherapy for early stage breast cancer. Nat Rev Clin Oncol. 2009;7(1):22–36.CrossRefPubMed
6.
Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26(12):1987–92.CrossRefPubMed
7.
Montemurro M, Aglietta M. Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy. Endocr Relat Cancer. 2009;16(4):1091–1102.CrossRefPubMed
8.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in Her2-positive breast cancer. N Engl J Med. 2005;353:1659–72.CrossRefPubMed
9.
Viani GA, Afonso SL, Stefano AJ, et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153.CrossRefPubMed
10.
Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28:509–918.CrossRefPubMed
11.
Seruga B, Ocana A, Niraula S, et al. Absolute benefits of aromatase inhibitors in adjuvant treatment of breast cancer: should we know more? J Clin Oncol. 2010;28:346–7.CrossRef
12.
Hinestrosa MC, Dickersin K, Klein P, et al. Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nature. 2007;7:309–15.
13.
Mc Shane LM, Altmann DG, Sauerbrei W, et al. Reporting recommendations for tumour marker prognostic studies. J Clin Oncol. 2005;23:9067–72.CrossRef
14.
Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Rel Cancer. 2010;17:245–62.CrossRef
15.
Jensen EV, Desombre ER, Hurst DJ, et al. Estrogen receptor interactions in target tissues. Arch Anat Microsc Morphol Exp. 1967;56:547–69.PubMed
16.
Mc Guire WL. Estrogen receptors in human breast cancer. J Clin Invest. 1973;52:73–7.CrossRef
17.
Fisher B, Redmond A, Brown A, et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med. 1981;305:1–6.CrossRefPubMed
18.
Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 2011;11:597–608.CrossRefPubMed
19.
Yu KD, Shao ZM. ESR1 gene amplification: another mechanism regulating the cellular levels of ER-a. Nat Rev Cancer. 2011;11:823.CrossRefPubMed
20.
Hammond EMH, Haye DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–95.CrossRefPubMed
21.
Lydon JP, Edwards DP. Finally! A model for progesterone receptor action in normal human breast. Endocrinology. 2009;150(7):2988.CrossRefPubMed
22.
Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007;25(25):3846–52.CrossRefPubMed
23.
Wolff AC, Hammond ME, Schwartz JN, et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.CrossRefPubMed
24.
Perez EA, Dueck AC, McCullough AE, et al. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP Her2 positive criteria. J Natl Cancer Inst. 2012;104(2):159–62.CrossRefPubMed
25.
Bartlett JM, Munro AF, Dunn JA, et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol. 2010;11(3):266–74.CrossRefPubMed
26.
Luprsi E, Andre F, Spyratos F, et al. KI 67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. BC Res Treat. 2011.
27.
Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65.CrossRefPubMed
28.
Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28(11):1829–34.CrossRefPubMed
29.
Macis D, Cazzaniga M, De Censi A, et al. Role of traditional and new biomarkers in breast cancer carcinogenesis. ecancer. 2009;3:157.
Metadaten
Titel
The role of biomarkers in the choice of therapy in breast cancer
verfasst von
Brigitte Mlineritsch, MD
Sigrun Ressler, MD
Prof. Richard Greil, MD
Publikationsdatum
01.06.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0027-y

Weitere Artikel der Ausgabe 2/2012

Natural killer cell based immunotherapy for eradication of minimal residual disease in patients with malignant disorders

  • short review

The role of Positron Emission Tomography/Computer Tomography (PET/CT) in the diagnosis, staging, characterization, and therapy of breast cancer

  • short review

Surgical removal of the primary?—The role it plays in stage IV breast cancer

  • short review

Advances in haematology and oncology 2011: hepatocellular carcinoma (HCC)

  • comment

Immunotherapeutic approaches targeting prostate cancer and its microenvironment

  • short review

Cellular immunotherapy for cancer. Past, present, future

  • editorial